Georgia SAT PharmD, BCOP Assistant Professor of Pharmacy Practice Philadelphia College of Osteopathic Medicine School of Pharmacy-Georgia Campus Suwanee. Chemotherapy agents that cause cardiotoxicity [Internet]. Available from: https://www.uspharmacist.com/article/chemotherapy-agents-that-cause-cardiotoxicity. Accessed 13 Nov 2022.

Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280–99.

Article  PubMed  Google Scholar 

de Boer RA, Aboumsallem JP, Bracun V, Leedy D, Cheng R, Patel S, et al. A new classification of cardio-oncology syndromes. Cardiooncology. 2021;7:24.

PubMed  PubMed Central  Google Scholar 

Kwan ML, Cheng RK, Iribarren C, Shen H, Laurent CA, Roh JM, et al. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat. 2022;193:669–75.

Article  PubMed  PubMed Central  Google Scholar 

• Reding KW, Cheng RK, Vasbinder A, Ray RM, Barac A, Eaton CB, et al. Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors. JACC CardioOncol. 2022;4:53–65.

Article  PubMed  PubMed Central  Google Scholar 

Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985–2010. JAMA Netw Open. 2023;6:e2254669.

Article  PubMed  PubMed Central  Google Scholar 

• Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018;11:e004962.

Article  PubMed  Google Scholar 

Brown S-AN, Doolittle DA, Bohanon CJ, Jayaraj A, Naidu SG, Huettl EA, et al. Quadrilateral space syndrome: the Mayo Clinic experience with a new classification system and case series. Mayo Clin Proc. 2015;90:382–94.

Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–14.

Article  PubMed  PubMed Central  Google Scholar 

Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer: background evidence and research perspectives. Circulation. 2018;138:735–42.

Article  PubMed  Google Scholar 

Yeboah J, Bertoni A, Qureshi W, Aggarwal S, Lima JAC, Kawel-Boehm N, et al. Pedal edema as an indicator of early heart failure in the community: prevalence and associations with cardiac structure/function and natriuretic peptides (MESA [Multiethnic Study of Atherosclerosis]). Circ Heart Fail. 2016;9:e003415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15.

Article  CAS  PubMed  Google Scholar 

Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.

Article  CAS  PubMed  Google Scholar 

Klein R, Nadouri D, Osler E, Johnson C, Dent S, Dwivedi G. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. Nucl Med Commun. 2019;40:22–9.

Article  CAS  PubMed  Google Scholar 

Kataoka H. Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines. Clin Cardiol. 2013;36:555–9.

Article  PubMed  PubMed Central  Google Scholar 

Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O’Reilly EM, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol. 2003;26:247–51.

Article  CAS  PubMed  Google Scholar 

Katsenos S, Nikolopoulou M. Gemcitabine-induced severe peripheral edema in a patient with lung cancer. J Pharm Pract. 2012;25:393–5.

Article  PubMed  Google Scholar 

Yang Y, Liu Y-H, Sun X, Yu M-W, Yang L, Cheng P-Y, et al. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. Curr Med Res Opin. 2017;33:1663–75.

Article  CAS  PubMed  Google Scholar 

Tm O, A M, Jw R, Kw R, S M, Jc P, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circulation Genomic and precision medicine [Internet]. Circ Genom Precis Med; 2021;14. Available from: https://pubmed.ncbi.nlm.nih.gov/33896190/. Accessed 13 Nov 2022.

Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VM, et al. Fatal heart disease among cancer patients. Nat Commun. 2020;11:2011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-1032.

PubMed  Google Scholar 

Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.

Article  PubMed  Google Scholar 

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.

Article  PubMed  PubMed Central  Google Scholar 

Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004;287:H963-968.

Article  PubMed  Google Scholar 

Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58–65.

Article  CAS  PubMed  Google Scholar 

Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 1996;14:422–8.

Article  CAS  PubMed  Google Scholar 

Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149–55.

Article  CAS  PubMed  Google Scholar 

Lexicomp. (n.d.). Docetaxel: Drug information. [Internet]. Available from: https://www.uptodate.com. Accessed 9 Feb 2023.

Largeau B, Cracowski J-L, Lengellé C, Sautenet B, Jonville-Béra A-P. Drug-induced peripheral oedema: an aetiology-based review. Br J Clin Pharmacol. 2021;87:3043–55.

Article  PubMed  Google Scholar 

Hamo CE, Bloom MW. Cancer and Heart Failure: understanding the Intersection. Card Fail Rev. 2017;3:66–70.

Article  PubMed  PubMed Central  Google Scholar 

Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Bucur). 2013;8:59–67.

PubMed  PubMed Central  Google Scholar 

Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta. 2006;1760:267–71.

Article  CAS  PubMed  Google Scholar 

Rassy EE, Assi T, Rizkallah J, Kattan J. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy. 2017;9:309–11.

Article  PubMed  Google Scholar 

Pedrinelli R, Dell’Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35:621–5.

Article  CAS  PubMed  Google Scholar 

Lexicomp App [Internet]. [cited 2023 Feb 24]. Available from: uptodate.com.

Minegishi S, Kinguchi S, Horita N, Namkoong H, Briasoulis A, Ishigami T, et al. Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis. Hypertension. 2022;79:2611–21.

Article  CAS  PubMed  Google Scholar 

•• Cohen JB, Brown NJ, Brown S-A, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80:e46-57.

Article  CAS  PubMed  Google Scholar 

van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128:1040–61.

Article  PubMed  PubMed Central  Google Scholar 

Solimando DA, Phillips ET, Weiss RB, Dawson NA, Diehl LF, Rickles NM. Hypertensive reactions associated with paclitaxel. Cancer Invest. 1996;14:340–2.

Article  CAS  PubMed  Google Scholar 

Biglia N, Zanfagnin V, Daniele A, Robba E, Bounous VE. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res. 2017;37:4005–15.

PubMed  Google Scholar